Literature DB >> 11327265

Treatment of Felty's syndrome with leflunomide.

F Talip1, N Walker, W Khan, B Zimmermann.   

Abstract

Felty's syndrome (FS) is a rare manifestation of severe rheumatoid arthritis (RA). It is an immune mediated inflammatory process, usually treated with standard disease modifying antirheumatic drugs. We describe a case of severe FS that developed in a patient receiving methotrexate therapy for RA. Treatment with etanercept resulted in severe allergic cutaneous reactions. The patient subsequently responded to treatment with leflunomide. The response included dramatic improvement of leukopenia and neutropenia as well as excellent control of his arthritis. Leflunomide has recently been used effectively for the treatment of RA and may be useful for the management of patients with FS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11327265

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

1.  Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study.

Authors:  J M van Woerkom; A A Kruize; R Geenen; E N van Roon; R Goldschmeding; S M M Verstappen; J A G van Roon; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

2.  Presentation of three cases followed up with a diagnosis of Felty syndrome.

Authors:  Ayten Yazıcı; Ayşenur Uçar; Özgür Mehtap; Emel Örge Gönüllü; Ali Tamer
Journal:  Eur J Rheumatol       Date:  2014-09-01

3.  The Diagnosis Felt(y) Right: A Case Report of Felty Syndrome With Limited Articular Involvement.

Authors:  Victor E Serrano Santiago; Zack Morgan
Journal:  Cureus       Date:  2022-04-29

Review 4.  Primary and secondary autoimmune neutropenia.

Authors:  Franco Capsoni; Piercarlo Sarzi-Puttini; Alberto Zanella
Journal:  Arthritis Res Ther       Date:  2005-08-31       Impact factor: 5.156

5.  Rapidly Progressive Felty Syndrome After Sudden Discontinuation of Methotrexate: A Case Report and Review of Literature.

Authors:  Suaad Hamsho; Isam Alannouf; Anas A Ashour
Journal:  Int Med Case Rep J       Date:  2022-09-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.